Home>>Signaling Pathways>> Proteases>> MMP>>Doxycycline HCl

Doxycycline HCl

Catalog No.GC13750

Doxycycline HCl, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

Doxycycline HCl Chemical Structure

Cas No.: 10592-13-9

Size Price Stock Qty
10mM (in 1mL DMSO)
$36.00
In stock
50mg
$49.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1].

Doxycycline hydrochloride affects growth of glioma cells only under high concentrations[2]. Doxycycline hydrochloride decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells[2].

Doxycycline hydrochloride (oral; 200 or 800 mg/kg/day; for 3 months) reduces active MMP-9 in untreated HT mice in a dose-dependent manner[1]

References:
[1]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.
[2]. Luger AL, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5).

Reviews

Review for Doxycycline HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Doxycycline HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.